CD72, a New Immune Checkpoint Molecule, is a Novel Prognostic Biomarker for Kidney Renal Clear Cell Carcinoma

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2023 Nov 19

PMID 37980541

Authors

Lv Tian

Yiming Wang

Zhiyuan Zhang

Xuechao Feng

Fengjun Xiao

Minru Zong

Affiliations

Soon will be listed here.

Abstract

Background: The incidence and mortality of clear cell carcinoma of the kidney increases yearly. There are limited screening methods and advances in treating kidney renal clear cell carcinoma (KIRC). It is important to find new biomarkers to screen, diagnose and predict the prognosis of KIRC. Some studies have shown that CD72 influences the development and progression of colorectal cancer, nasopharyngeal cancer, and acute lymphoid leukemia. However, there is a lack of research on the role of CD72 in the pathogenesis of KIRC. This study aimed to determine whether CD72 is associated with the prognosis and immune infiltration of KIRC, providing an essential molecular basis for the early non-invasive diagnosis and immunotherapy of KIRC.

Methods: Using TCGA, GTE, GEO, and ImmPort databases, we obtained the differentially expressed mRNA (DEmRNA) associated with the prognosis and immunity of KIRC patients. We used the Kruskal-Wallis test to identify clinicopathological parameters associated with target gene expression. We performed univariate and multivariate COX regression analyses to determine the effect of target gene expression and clinicopathological parameters on survival. We analyzed the target genes' relevant functions and signaling pathways through enrichment analysis. Finally, the correlation of target genes with tumor immune infiltration was explored by ssGSEA and Spearman correlation analysis.

Results: The results revealed that patients with KIRC with higher expression of CD72 have a poorer prognosis. CD72 was associated with the Pathologic T stage, Pathologic stage, Pathologic M stage, Pathologic N stage, Histologic grade in KIRC patients, Laterality, and OS event. It was an independent predictor of the overall survival of KIRC patients. Functional enrichment analysis showed that CD72 was significantly enriched in oncogenic and immune-related pathways. According to ssGSEA and Spearman correlation analysis, CD72 expression was significantly associated with tumor immune cells and immune checkpoints.

Conclusion: Our study suggests that CD72 is associated with tumor immunity and may be a biomarker relevant to the diagnosis and prognosis of KIRC patients.

Citing Articles

Prognostic Value and Immunological Role of POP7 in Clear Cell Renal Cell Carcinoma.

Lou N, Meng X, Yu T, Li W, Lv X, Han W Pharmgenomics Pers Med. 2024; 17:521-534.

PMID: 39620194 PMC: 11608043. DOI: 10.2147/PGPM.S469247.

References

Hernandez Borrero L, El-Deiry W . Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021; 1876(1):188556. PMC: 8730328. DOI: 10.1016/j.bbcan.2021.188556. View

Nitschke L, Tsubata T . Molecular interactions regulate BCR signal inhibition by CD22 and CD72. Trends Immunol. 2004; 25(10):543-50. DOI: 10.1016/j.it.2004.08.002. View

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

De Marco S, Torsello B, Minutiello E, Morabito I, Grasselli C, Bombelli S . The cross-talk between Abl2 tyrosine kinase and TGFβ1 signalling modulates the invasion of clear cell Renal Cell Carcinoma cells. FEBS Lett. 2022; 597(8):1098-1113. DOI: 10.1002/1873-3468.14531. View

Adachi T, Wakabayashi C, Nakayama T, Yakura H, Tsubata T . CD72 negatively regulates signaling through the antigen receptor of B cells. J Immunol. 2000; 164(3):1223-9. DOI: 10.4049/jimmunol.164.3.1223. View

Gruosso T, Mieulet V, Cardon M, Bourachot B, Kieffer Y, Devun F . Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients. EMBO Mol Med. 2016; 8(5):527-49. PMC: 5123617. DOI: 10.15252/emmm.201505891. View

Kikutani H, Kumanogoh A . Semaphorins in interactions between T cells and antigen-presenting cells. Nat Rev Immunol. 2003; 3(2):159-67. DOI: 10.1038/nri1003. View

McFarlane R, Wakeman J . Meiosis-like Functions in Oncogenesis: A New View of Cancer. Cancer Res. 2017; 77(21):5712-5716. DOI: 10.1158/0008-5472.CAN-17-1535. View

10.

Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M . New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2011; 117(23):6267-76. PMC: 3122946. DOI: 10.1182/blood-2010-12-324004. View

11.

Pan C, Baumgarth N, Parnes J . CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation. Immunity. 1999; 11(4):495-506. DOI: 10.1016/s1074-7613(00)80124-7. View

12.

Lucarelli G, Loizzo D, Franzin R, Battaglia S, Ferro M, Cantiello F . Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 2019; 19(5):397-407. DOI: 10.1080/14737159.2019.1607729. View

13.

Tamma R, Rutigliano M, Lucarelli G, Annese T, Ruggieri S, Cascardi E . Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment. Urol Oncol. 2019; 37(6):355.e11-355.e19. DOI: 10.1016/j.urolonc.2019.01.025. View

14.

Qian B, Pollard J . Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141(1):39-51. PMC: 4994190. DOI: 10.1016/j.cell.2010.03.014. View

15.

Sceneay J, Smyth M, Moller A . The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 2013; 32(3-4):449-64. DOI: 10.1007/s10555-013-9420-1. View

16.

Chen H, Xie J, Jin P . Assessment of hazard immune-related genes and tumor immune infiltrations in renal cell carcinoma. Am J Transl Res. 2020; 12(11):7096-7113. PMC: 7724327. View

17.

Lucarelli G, Rutigliano M, Loizzo D, di Meo N, Lasorsa F, Mastropasqua M . MUC1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor Clinical Outcome. Int J Mol Sci. 2022; 23(22). PMC: 9696833. DOI: 10.3390/ijms232213968. View

18.

Nacev B, Feng L, Bagert J, Lemiesz A, Gao J, Soshnev A . The expanding landscape of 'oncohistone' mutations in human cancers. Nature. 2019; 567(7749):473-478. PMC: 6512987. DOI: 10.1038/s41586-019-1038-1. View

19.

Wu H, Han Y, Rodriguez Sillke Y, Deng H, Siddiqui S, Treese C . Lipid droplet-dependent fatty acid metabolism controls the immune suppressive phenotype of tumor-associated macrophages. EMBO Mol Med. 2019; 11(11):e10698. PMC: 6835560. DOI: 10.15252/emmm.201910698. View

20.

Zhu Z, McGray A, Jiang W, Lu B, Kalinski P, Guo Z . Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Mol Cancer. 2022; 21(1):196. PMC: 9554963. DOI: 10.1186/s12943-022-01664-z. View